



Image

1/22/04

1632

Please type a plus sign (+) inside this box →



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/040,315
		Filing Date	October 29, 2001
		First Named Inventor	FARESE JR., ROBERT V.
		Group Art Unit	1632
		Examiner Name	BERTOGLIO, VALERIE E.
Total Number of Pages in This Submission	3	Attorney Docket Number	UCAL-105CIP2
ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1) Response to Restriction Requirement (2 pgs.) 2) Return Postcard	Remarks
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Signing Attorney/Agent (Reg. No.)	PAULA A. BORDEN, 42,344 BOZICEVIC, FIELD & FRANCIS LLP		
Signature			
Date	January 20, 2004		

EXPRESS MAIL LABEL NO. EV333998494US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. **EV333998494US**

**RESPONSE TO RESTRICTION
REQUIREMENT**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attorney Docket
(Confirmation No.) UCAL105CIP2
1732

First Named Inventor R.V. Farese, Jr.

Application Number 10/040,315

Filing Date October 29, 2001

Group Art Unit 1632

Examiner Name V.E. Bertoglio

Title: *Diacylglycerol O-acyltransferase*


Sir:

This is in response to the Restriction Requirement dated December 17, 2003. The Restriction Requirement set forth a one-month time period for response, making a response due on or before **January 17, 2004**. January 17, 2004 fell on a Saturday; and January 19, 2004 was a U.S. federal holiday. This response is being filed on January 20, 2004, the next business day. Accordingly, this response is timely filed.

I. REMARKS

In the Restriction Requirement, the Examiner required election of one of the following groups of claims:

- Group I: Claims 1-9 and 20-23, drawn to a non-human animal characterized by having a knockout allele of the naturally occurring, endogenous DGAT gene and a method of using an animal to test a candidate agent for DGAT function modulatory activity;
- Group II: Claims 10-14 and 19, drawn to cells in vitro and an in vitro cellular assay for screening candidate agents for modulatory activity of DGAT function using said cells;
- Group III: Claim 19 drawn to a cell free assay for screening candidate agents for modulatory activity of DGAT function;
- Group IV: Claim 26, drawn to an in vitro, cellular assay for screening candidate agents for modulatory activity of DGAT expression;
- Group V: Claim 26, drawn to an in vitro, cellular assay for screening candidate agents for modulatory activity of DGAT expression; and



Atty Dkt. No.: UCAL105CIP2
USSN: 10/040,315

Group VI: Claim 27, drawn to an in vivo assay for screening candidate agents for modulatory activity of DGAT expression.

Applicants hereby elect to prosecute the claims of Group II (claims 10-14 and 19), with traverse. Applicants expressly reserve the right under 35 USC §121 to file one or more divisional applications directed to the non-elected subject matter during the pendency of this application.


This election is made with traverse. As stated in the MPEP §803, if search and examination of an entire application can be made without serious burden, the examiner must examine it on the merits, even though it includes claims to independent or distinct inventions. It is Applicants' position that it would not be unduly burdensome to perform a search on claims 1-29 together. Accordingly, Applicants traverse the restriction requirement.

II. CONCLUSION

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number UCAL105CIP2.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: Jan. 20, 2004

By: 
Paula A. Borden
Registration No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231